[Functional evaluation in patients with pulmonary tuberculosis sequelae]. 2011

F C Di Naso, and J S Pereira, and S J Schuh, and G Unis
Serviço de Fisioterapia, Hospital Sanatório Partenon, Porto Alegre (RS), Brasil. fdinaso@yahoo.com.br

BACKGROUND In pulmonary tuberculosis, the presence of extensive residual lung lesions can be a predictor of permanent disability due to respiratory failure. OBJECTIVE To compare functional and respiratory changes in patients with pulmonary tuberculosis sequel who have completed treatment. METHODS The study included patients who completed treatment within a period of 6 months (group I) and multidrug-resistant pulmonary tuberculosis patients who completed treatments of longer duration after the failure of the initial treatment (group II). We evaluated lung function by spirometry (Microlab ML 3500), the strength of respiratory muscles through the manovacuometry (MEP-maximal expiratory pressure and MIP- maximal inspiratory pressure) and the distance walked during the 6-minute walk (6MWT). RESULTS 27 patients were included, 12 of whom belonged to group II, multidrug-resistant tuberculosis (MDRTB). Severe combined respiratory disorder was the most prevalent problem in group II of MDRTB; it was present in 9 patients. The MDRTB group (group II) showed significantly lower values when compared to Group I in FVC (72.06±14.95 vs 43.58±16.03% predicted), FEV1 (66.13±19.87 vs 33.08±15.64% predicted), MIP (68.40±22.78 vs 49.58±12.55 cmH(2)O), MEP (87.20±27.30 vs 59.08±12.23 cmH(2)O) and distance covered in 6MWT (484.21±74.01 vs 334.75±104.07 meters). CONCLUSIONS Patients with multidrug resistant pulmonary tuberculosis who have undergone multiple treatments have more severe respiratory and functional impairment than patients who have had just a single treatment.

UI MeSH Term Description Entries
D008297 Male Males
D012129 Respiratory Function Tests Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc. Lung Function Tests,Pulmonary Function Tests,Function Test, Pulmonary,Function Tests, Pulmonary,Pulmonary Function Test,Test, Pulmonary Function,Tests, Pulmonary Function,Function Test, Lung,Function Test, Respiratory,Function Tests, Lung,Function Tests, Respiratory,Lung Function Test,Respiratory Function Test,Test, Lung Function,Test, Respiratory Function,Tests, Lung Function,Tests, Respiratory Function
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014397 Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung. Pulmonary Consumption,Pulmonary Phthisis,Pulmonary Tuberculoses,Pulmonary Tuberculosis,Tuberculoses, Pulmonary,Consumption, Pulmonary,Consumptions, Pulmonary,Phthises, Pulmonary,Phthisis, Pulmonary,Pulmonary Consumptions,Pulmonary Phthises
D018088 Tuberculosis, Multidrug-Resistant Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS. Tuberculosis, Drug-Resistant,Tuberculosis, MDR,Tuberculosis, Multi-Drug Resistant,Drug-Resistant Tuberculosis,MDR Tuberculosis,Multi-Drug Resistant Tuberculosis,Multidrug-Resistant Tuberculosis,Tuberculosis, Drug Resistant,Tuberculosis, Multi Drug Resistant,Tuberculosis, Multidrug Resistant

Related Publications

F C Di Naso, and J S Pereira, and S J Schuh, and G Unis
April 2024, The Indian journal of tuberculosis,
F C Di Naso, and J S Pereira, and S J Schuh, and G Unis
January 1971, Lotta contro la tubercolosi,
F C Di Naso, and J S Pereira, and S J Schuh, and G Unis
April 2002, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
F C Di Naso, and J S Pereira, and S J Schuh, and G Unis
March 2019, The European respiratory journal,
F C Di Naso, and J S Pereira, and S J Schuh, and G Unis
January 1976, Le Poumon et le coeur,
F C Di Naso, and J S Pereira, and S J Schuh, and G Unis
January 1988, Kekkaku : [Tuberculosis],
F C Di Naso, and J S Pereira, and S J Schuh, and G Unis
October 1997, Chest,
F C Di Naso, and J S Pereira, and S J Schuh, and G Unis
January 2010, Internal medicine (Tokyo, Japan),
F C Di Naso, and J S Pereira, and S J Schuh, and G Unis
January 1988, Kekkaku : [Tuberculosis],
F C Di Naso, and J S Pereira, and S J Schuh, and G Unis
January 2006, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia,
Copied contents to your clipboard!